Vascular Solutions to Present at the 34th Annual Canaccord Genuity Growth Conference
July 30 2014 - 4:05PM
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the
Company is scheduled to present at the 34th Annual Canaccord
Genuity Growth Conference in Boston on Thursday, August 14th at
2:00pm (EDT).
Howard Root, Chief Executive Officer of Vascular Solutions, will
deliver the Company's presentation. To hear the live audio webcast
and view the slides of the Vascular Solutions' presentation, go to
the investor relations page of the Company's web site www.vasc.com
and click on the "Investor Conferences" icon a few minutes prior to
start time to download any necessary software.
About Canaccord Genuity
Canaccord Genuity is a leading independent financial services
firm committed to fostering the entrepreneurial economy by bringing
corporate and institutional clients a unique perspective on global
investment opportunities. More information is available at
www.canaccordgenuity.com.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company
that focuses on developing unique clinical solutions for coronary
and peripheral vascular procedures. The company's product line
consists of more than 80 products in three categories: catheter
products, hemostat products and vein products. Vascular Solutions
delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein
specialists through its direct U.S. sales force and international
independent distributor network.
The information in this press release contains forward-looking
statements that involve risks and uncertainties. Our actual results
could differ materially from those anticipated in these
forward-looking statements. Important factors that may cause such
differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2013 and other recent filings
with the Securities and Exchange Commission. The risks and
uncertainties include, without limitation, risks associated with
the need for adoption of our new products, lack of sustained
profitability, exposure to intellectual property claims,
significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by
others, doing business in international markets, the availability
of third party reimbursement, and actions by the FDA.
CONTACT: James Hennen, CFO
Phil Nalbone, VP
Vascular Solutions, Inc.
(763) 656-4300
Vascular Solutions, Inc. (NASDAQ:VASC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Solutions, Inc. (NASDAQ:VASC)
Historical Stock Chart
From Sep 2023 to Sep 2024